Because SGLT2 inhibitor, which was used for the treatment of DM, has an effect on transaminase and hepatic fat content,22, 23 we analyzed the 26 pemafibrate‐treated NAFLD patients who did not receive the SGLT2 inhibitor, resulting in a tendency to improve the FAST score. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.